loader
Please Wait
Applying Filters...

List of NCGC00024890-06 Active Pharmaceutical Ingredient (API) suppliers/manufacturers & exporters

Client Email Product
Left Arrow
Right Arrow
Filters Filter
×
FILTER DATA :

filter

Dalfampridine

Fampridine

filter

INDIA

ITALY

SPAIN

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 count...
Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 countries including regulated markets. Formulations Centaur ranks among India's TOP 50 pharmaceutical companies by prescriptions (CMarc) and by stockist audit (ORG-IMS). Centaur's All-India network includes a 1000 strong sales force that covers 250,000 doctors and 250,000 retailers every month. Over 50 million prescriptions of Centaur brands are generated by doctors of all specialities, annually. Prescription audits (ORG-IMS & CMarc) confirm that Sinarest is a clear leader in the Indian Anti-Cold market. One prescription of Sinarest is generated every second by a doctor in India! Centaur has demonstrated its competence in transforming products into strong brands, reinforced by successful extensions, resulting in a formidable presence in key therapy areas. Centaur brands are leaders in six therapeutic segments and rank among the top 3 in six other therapeutic segments. Centaur's manufacturing facilities at GOA conform to WHO-GMP standards, and dosage forms include tablets liquids, injectables (vials and ampoules), eye and ear drops, and ointments. CRAM The current pharma scenario has driven a shift, away from in-house R&D and production to contract research and manufacturing (CRAM). A fully scalable 25,000 square metres formulations facility conforming to USFDA / EU standards has been set up in Pune with a focus on oral solids. API Centaur is India's largest manufacturer and exporter of Psychotropic API and have introduced 24 API for the first time in India. Our API manufacturing facility near Mumbai conforms to USFDA standards and our clientele includes Big Pharma, generic majors and Indian multinationals. Our specialisation ranges from API and intermediates to custom synthesis and process chemistry. An integrated approach ensures that we can scale up capabilities from conceptualisation to commercialisation. CRO A 10,000 square feet, ultra-modern, contract research organisation (CRO) with a 36 bed clinical pharmacology unit (CPU), has been set up at Centaur House, our corporate headquarters. Facilities include Bio-availability (BA), Bio-equivalence (BE), Bio-analysis & Clinical trials. State-of-the-art R&D laboratories dedicated to formulations and API, approved by the Government of India are also located at Centaur House. Future By strategically positioning itself for collaborative relationships, Centaur has tied up with the world's leading players, by offering high performance value options and critical capabilities. We believe that our core competencies in API, formulations, CRAM and CRO will enhance business volumes and help us ascend the pharmaceutical value chain. This would help us realise our vision of emerging as a 'fully integrated global pharmaceutical player'.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, and starts business activities trading with pharmaceutical raw materials. In the 80's, the company expanded its operations into the Industrial Business, developing and ma...
More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, and starts business activities trading with pharmaceutical raw materials. In the 80's, the company expanded its operations into the Industrial Business, developing and manufacturing active pharmaceutical ingredients (APIs) in Italy (Industriale Chimica) and in Spain (Quimica Sintetica). In the 90's, CHEMO starts developing and manufacturing high quality and technology finished dosage forms (FDFs).

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven products at competitive prices, thus providing the critical India advantage to generic formulators across the world. The paradigm shift of leading Indian pharmaceutical compan...
Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven products at competitive prices, thus providing the critical India advantage to generic formulators across the world. The paradigm shift of leading Indian pharmaceutical companies to target high volume and blockbuster products for regulated markets has been the inspiration behind the launch of Enaltec Labs. The vision of Enaltec Labs is to be a partner of Global Healthcare Industry for supplying High Quality APIs at Competitive Prices Complying with Stringent Regulatory Requirements. Enaltec Labs is one of the few independent Indian API suppliers with world class infrastructure, having no intention of competing with its customers in their home market. The manufacturing facility at Ambernath is WHO GMP approved and US FDA Inspected & complaint.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven products at competitive prices, thus providing the critical India advantage to generic formulators across the world. The paradigm shift of leading Indian pharmaceutical compan...
Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven products at competitive prices, thus providing the critical India advantage to generic formulators across the world. The paradigm shift of leading Indian pharmaceutical companies to target high volume and blockbuster products for regulated markets has been the inspiration behind the launch of Enaltec Labs. The vision of Enaltec Labs is to be a partner of Global Healthcare Industry for supplying High Quality APIs at Competitive Prices Complying with Stringent Regulatory Requirements. Enaltec Labs is one of the few independent Indian API suppliers with world class infrastructure, having no intention of competing with its customers in their home market. The manufacturing facility at Ambernath is WHO GMP approved and US FDA Inspected & complaint.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Developm...
Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. Our success is an outcome of strategic focus on the pharmaceuticals and life sciences industry, moving up the pharmaceutical value chain for products and services across geographies, constantly investing in various growth platforms and promoting a culture of innovation. Jubilant Life Sciences has been ranked No. 6 amongst the Top 10 global contract manufacturing & services outsourcing players of the pharmaceutical industry (Source: UNCTAD, 2011). We are engaged in continuous improvement of products and processes to enhance the quality of production and cost competitiveness in order to build value for our customers. Jubilant Life Sciences serves its customers globally with sales in over 100 countries and ground presence in India, North America, Europe and China. We are well recognised as a ‘Partner of Choice’ by leading life sciences companies worldwide. Jubilant has relationship with 19 of Top 20 pharmaceutical companies and 6 amongst top 10 agrochemical companies across the globe. Over the years, Jubilant Life Sciences has extended its footprint beyond India in the USA, Canada, Europe, and other countries across the globe. We have also expanded the business by building capabilities internally, through strategic expansions and acquisitions This resulted in a network of 7 world class manufacturing facilities in India and 3 in North America and a team of around 6200 multicultural people across the globe with ~ 1400 in North America and ~1000 in R&D. Our multi-location presence helps us in getting closer to customers and serving them better with the best in class products developed most efficiently, economically with speed to market. Jubilant Life Sciences' progress in diverse businesses has been made possible through the contribution of R&D; for quality, non-infringing process for product development and cost reduction through process innovation. Innovation at Jubilant is backed by strong chemistry, bio science expertise and the knowledge bank created over the years. We have harnessed our strengths – a strong R&D team, modern R&D facilities, command over cheap technologies and economies of scale into a synergistic organic entity, continuously creating and nurturing high quality products and technologies. In line with Jubilant Life Sciences continued focus on sustainability of business, we aim at improving stakeholder value through improved eco efficient use of capital and natural resources. Jubilant’s approach to sustainable development focuses on the triple bottom line of Economics, Environment and Social performance. We are committed and working on various areas for energy conservation and climate change mitigation. Our sustainability efforts have been reported through a Corporate Sustainability Report since 2003 and this report has been receiving GRI G3.1 A+ level & GRI Check, since 2007 from Global Reporting Initiative (GRI). This reflects Jubilant Life Sciences commitment towards sustainable development and continued efforts directed towards protecting the environment wherever we operate. Healthcare Solutions through Synergy Corporate Social Responsibility is an integral part of how Jubilant Life Sciences conducts business and how the efforts are directed towards community development through focus on primary education, basic healthcare service, and livelihood generation programs focused on improving the employability of women and local youth. We have been recognised with several awards and recognitions, which bear testimony to our commitment towards operational excellence, innovation, corporate governance and social responsibility. Jubilant Life Sciences is committed to leverage innovation and scale of operations at every step of the pharmaceutical value chain to deliver value to our stakeholders.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates and related services for the pharmaceutical industry. Our core business sectors include custom synthesis and Generic API manufacturing. ...
Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates and related services for the pharmaceutical industry. Our core business sectors include custom synthesis and Generic API manufacturing. The manufacturing site is located in Cameri, Italy. This 110,000 sq. meter, cutting-edge multipurpose plant, fully designed under cGMP compliance, has been successfully audited and approved by the main regulatory authorities including AIFA, FDA and PMDA.

PharmaCompass >>

First
Previous
Next
Last